
The earnings season came to a close with Germany’s Merck doubling its first-quarter profits. For the week, drug trials, analyst …

Valeant Pharmaceuticals Inc (NYSE: VRX) cut its outlook for the first-quarter of 2016 and posted a loss for the final …

